Literature DB >> 8114512

Antiinflammatory steroids inhibit granulocyte/macrophage colony-stimulating factor production by human lung tissue.

M Kato1, R P Schleimer.   

Abstract

Granulocyte/macrophage colony-stimulating factor (GM-CSF) is an important hematopoietic growth factor which has been shown to induce proliferation and activation of inflammatory cells, and may play a role in allergic diseases and experimental allergic reactions. Since little is known about the involvement of cytokines in allergic inflammation in the lung, we investigated whether human lung fragments produce GM-CSF in vitro. The present studies demonstrate that human lung fragments produce GM-CSF in vitro and that glucocorticoids are potent inhibitors of this cytokine production. Human lung was cut into fragments, rinsed, and cultured in 60-mm tissue culture plates containing 50 mg of tissue in RPMI 1640 with antibiotics in the presence or absence of a variety of steroids for 18 h. Lung fragments were rinsed and then incubated for an additional 4 h. Supernatants were harvested and analyzed for GM-CSF activity using the GM-CSF/interleukin (IL)-3 responsive M-07e human leukemic cell line. Steroids alone had no effect on M-07e proliferation. Human lung fragments produced 32.1 +/- 11.8 ng of GM-CSF equivalents per gram wet weight of tissue during the 4 h incubation (mean +/- S.E.M., n = 5, range 9.2-74.2). While specific antisera against human GM-CSF neutralized 96.8 +/- 2.8% (n = 5) of the activity, anti-IL-3 antibody had no effect, suggesting most or all of this activity was GM-CSF. Treatment of lung fragments in vitro for 18 h with hydrocortisone (HC) inhibited the production of GM-CSF dose-dependently. Maximal inhibition of GM-CSF production was 72.8 +/- 4.0% at a concentration of 10(-6) M hydrocortisone (n = 5), and the molar concentration of HC that inhibited of GM-CSF production by lung tissue by 50% (IC50) was approximately 4.5 x 10(-7) M. Kinetic studies revealed that a 6 h preincubation with the drug was required for 50% inhibition of GM-CSF production. HC and other glucocorticoids, at a concentration of 0.1 microM, demonstrated significant inhibition of GM-CSF release. Based on the rank order of potency of several glucocorticoids, and the fact that nonglucocorticoid steroids including testosterone and beta-estradiol (0.1 microM) had no effect, we suggest that this is a specific receptor-mediated effect. We conclude that human lung produces GM-CSF in vitro and that antiinflammatory steroids are potent and effective inhibitors of the production of this cytokine. This may contribute to the therapeutic efficacy of these drugs in pulmonary diseases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8114512     DOI: 10.1007/bf00185082

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  31 in total

1.  Modulation and induction of eosinophil chemotaxis by granulocyte-macrophage colony-stimulating factor and interleukin-3.

Authors:  R A Warringa; L Koenderman; P T Kok; J Kreukniet; P L Bruijnzeel
Journal:  Blood       Date:  1991-06-15       Impact factor: 22.113

2.  Regulatory effect of cytokines on eosinophil degranulation.

Authors:  T Fujisawa; R Abu-Ghazaleh; H Kita; C J Sanderson; G J Gleich
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

3.  The relationship between glucocorticoid structure and effects upon thymocytes.

Authors:  J P Dausse; D Duval; P Meyer; J C Gaignault; C Marchandeau; J P Raynaud
Journal:  Mol Pharmacol       Date:  1977-09       Impact factor: 4.436

4.  Transcriptional regulation of the interleukin 2 gene by glucocorticoid hormones. Role of steroid receptor and antigen-responsive 5'-flanking sequences.

Authors:  A Vacca; S Martinotti; I Screpanti; M Maroder; M P Felli; A R Farina; A Gismondi; A Santoni; L Frati; A Gulino
Journal:  J Biol Chem       Date:  1990-05-15       Impact factor: 5.157

5.  Dexamethasone and 1,25-dihydroxyvitamin D3, but not cyclosporine A, inhibit production of granulocyte-macrophage colony-stimulating factor in human fibroblasts.

Authors:  A Tobler; H P Marti; C Gimmi; A B Cachelin; S Saurer; M F Fey
Journal:  Blood       Date:  1991-05-01       Impact factor: 22.113

6.  Endobronchial allergen challenge in asthma. Demonstration of cellular source of granulocyte macrophage colony-stimulating factor by in situ hybridization.

Authors:  D H Broide; G S Firestein
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

7.  Production of granulocyte-macrophage colony-stimulating factor by cultured human tracheal epithelial cells.

Authors:  L Churchill; B Friedman; R P Schleimer; D Proud
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

8.  Interleukin-1 binds to specific receptors on human bronchial epithelial cells and upregulates granulocyte/macrophage colony-stimulating factor synthesis and release.

Authors:  M Marini; M Soloperto; M Mezzetti; A Fasoli; S Mattoli
Journal:  Am J Respir Cell Mol Biol       Date:  1991-06       Impact factor: 6.914

9.  Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA.

Authors:  S W Lee; A P Tsou; H Chan; J Thomas; K Petrie; E M Eugui; A C Allison
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

10.  Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts.

Authors:  W F Owen; M E Rothenberg; D S Silberstein; J C Gasson; R L Stevens; K F Austen; R J Soberman
Journal:  J Exp Med       Date:  1987-07-01       Impact factor: 14.307

View more
  2 in total

1.  Discovery of novel irreversible inhibitors of interleukin (IL)-2-inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket.

Authors:  John D Harling; Angela M Deakin; Sébastien Campos; Rachel Grimley; Laiq Chaudry; Catherine Nye; Oxana Polyakova; Christina M Bessant; Nick Barton; Don Somers; John Barrett; Rebecca H Graves; Laura Hanns; William J Kerr; Roberto Solari
Journal:  J Biol Chem       Date:  2013-08-09       Impact factor: 5.157

2.  The treatment of vasomotor rhinitis with intranasal corticosteroids.

Authors:  Eli O Meltzer
Journal:  World Allergy Organ J       Date:  2009-08-15       Impact factor: 4.084

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.